Early Insights From Clinical Trials of Typhoid Conjugate Vaccine

Kathleen M Neuzil; Buddha Basnyat; John D Clemens; Melita A Gordon; Priyanka D Patel; Andrew J Pollard; Mila Shakya; Firdausi Qadri

doi:10.1093/cid/ciaa370

Early Insights From Clinical Trials of Typhoid Conjugate Vaccine

Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S155-S159. doi: 10.1093/cid/ciaa370.

Authors

Kathleen M Neuzil¹, Buddha Basnyat², John D Clemens³, Melita A Gordon^{4

5}, Priyanka D Patel⁴, Andrew J Pollard^{6

7}, Mila Shakya², Firdausi Qadri³

Affiliations

¹ University of Maryland School of Medicine, Baltimore, Maryland, USA.
² Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal.
³ Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
⁴ Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
⁵ Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
⁶ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
⁷ National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.

Abstract

Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid conjugate vaccine.

Keywords: TyVAC; clinical trials; conjugate vaccine; typhoid.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Salmonella typhi
Typhoid Fever* / prevention & control
Typhoid-Paratyphoid Vaccines*
Vaccines, Conjugate
World Health Organization

Substances

Typhoid-Paratyphoid Vaccines
Vaccines, Conjugate